Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: Relevance to neural disorders

Fluids and Barriers of the CNS

Volumn 8, Issue 1, 2011, Pages

  Tachikawa, Masanori ^a   Hosoya, Ken Ichi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 GUANIDINOBUTYRIC ACID; AMINO ACID TRANSPORTER; ARGININE; ASPARTIC ACID; CREATINE; CREATINE PHOSPHATE; CREATINE TRANSPORTER; CREATININE; DEXTRO ASPARTIC ACID; GLUTAMIC ACID; GLYCINE; GLYCINE AMIDINOTRANSFERASE; GUANIDINE DERIVATIVE; GUANIDINOACETATE METHYLTRANSFERASE; GUANIDINOACETIC ACID; GUANIDINOPROPIONIC ACID; GUANIDINOSUCCINIC ACID; METHYLGUANIDINE; ORGANIC CATION TRANSPORTER; S ADENOSYLMETHIONINE; SERINE; TAURINE; TAURINE TRANSPORTER; UNCLASSIFIED DRUG;

AMINO ACID SYNTHESIS; AMINO ACID TRANSPORT; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN FUNCTION; CONVULSION; DEGENERATIVE DISEASE; DRUG EFFICACY; ENDOTHELIUM CELL; EPILEPTIC DISCHARGE; EPILEPTIC FOCUS; GABAERGIC TRANSMISSION; HUMAN; HUNTINGTON CHOREA; INTERSTITIAL FLUID; MICHAELIS MENTEN KINETICS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 79959944962     PISSN: None     EISSN: 20458118     Source Type: Journal    
DOI: 10.1186/2045-8118-8-13     Document Type: Review

References (87)

1. Hiramatsu M. A role for guanidino compounds in the brain. Mol Cell Biochem 2003, 244:57-62. 10.1023/A:1022491419813, 12701810.
2. Marescau B, De Deyn P, Wiechert P, Van Gorp L, Lowenthal A. Comparative study of guanidino compounds in serum and brain of mouse, rat, rabbit, and man. J Neurochem 1986, 46:717-720. 10.1111/j.1471-4159.1986.tb13030.x, 3950603.
3. Marescau B, Deshmukh DR, Kockx M, Possemiers I, Qureshi IA, Wiechert P, De Deyn PP. Guanidino compounds in serum, urine, liver, kidney, and brain of man and some ureotelic animals. Metabolism 1992, 41:526-532. 10.1016/0026-0495(92)90213-T, 1588833.
4. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000, 80:1107-1213.
5. Hosoya K, Hori S, Ohtsuki S, Terasaki T. A new in vitro model for blood-cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Adv Drug Deliv Rev 2004, 56:1875-1885. 10.1016/j.addr.2004.07.013, 15381338.
6. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007, 24:1745-1758. 10.1007/s11095-007-9374-5, 17619998.
7. Stockler S, Schutz PW, Salomons GS. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcell Biochem 2007, 46:149-166. full_text, 18652076.
8. Almeida LS, Verhoeven NM, Roos B, Valongo C, Cardoso ML, Vilarinho L, Salomons GS, Jakobs C. Creatine and guanidinoacetate: diagnostic markers for inborn errors in creatine biosynthesis and transport. Mol Genet Metab 2004, 82:214-219. 10.1016/j.ymgme.2004.05.001, 15234334.
9. Bianchi MC, Tosetti M, Fornai F, Alessandri MG, Cipriani P, De Vito G, Canapicchi R. Reversible brain creatine deficiency in two sisters with normal blood creatine level. Ann Neurol 2000, 47:511-513. 10.1002/1531-8249(200004)47:4<511::AID-ANA15>3.0.CO;2-N, 10762163.
10. Item CB, Stockler-Ipsiroglu S, Stromberger C, Muhl A, Alessandri MG, Bianchi MC, Tosetti M, Fornai F, Cioni G. Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans. Am J Hum Genet 2001, 69:1127-1133. 10.1086/323765, 1274356, 11555793.
11. Stockler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, Hanicke W, Frahm J. Creatine deficiency in the brain: a new, treatable inborn error of metabolism. Pediatr Res 1994, 36:409-413.
12. Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, Jakobs C. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am J Hum Genet 2001, 68:1497-1500. 10.1086/320595, 1226136, 11326334.
13. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001, 53:161-176.
14. Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol 1999, 277:R698-704.
15. Stockler S, Hanefeld F, Frahm J. Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet 1996, 348:789-790. 10.1016/S0140-6736(96)04116-5, 8813986.
16. Bizzi A, Bugiani M, Salomons GS, Hunneman DH, Moroni I, Estienne M, Danesi U, Jakobs C, Uziel G. X-linked creatine deficiency syndrome: a novel mutation in creatine transporter gene SLC6A8. Ann Neurol 2002, 52:227-231. 10.1002/ana.10246, 12210795.
17. Cecil KM, Salomons GS, Ball WS, Wong B, Chuck G, Verhoeven NM, Jakobs C, DeGrauw TJ. Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect?. Ann Neurol 2001, 49:401-404. 10.1002/ana.79, 11261517.
18. Poo-Arguelles P, Arias A, Vilaseca MA, Ribes A, Artuch R, Sans-Fito A, Moreno A, Jakobs C, Salomons G. X-Linked creatine transporter deficiency in two patients with severe mental retardation and autism. J Inherit Metab Dis 2006, 29:220-223. 10.1007/s10545-006-0212-4, 16601898.
19. Hiramatsu M, Edamatsu R, Fujikawa N, Shirasu A, Yamamoto M, Suzuki S, Mori A. Measurement during convulsions of guanidino compound levels in cerebrospinal fluid collected with a catheter inserted into the cisterna magna of rabbits. Brain Res 1988, 455:38-42. 10.1016/0006-8993(88)90111-4, 3416191.
20. Hosoya K, Yamamoto A, Akanuma S, Tachikawa M. Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability. Pharm Res 2010, 27:2715-2724. 10.1007/s11095-010-0272-x, 20859661.
21. Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab 2002, 22:1327-1335. 10.1097/00004647-200211000-00006, 12439290.
22. Tachikawa M, Hosoya K, Ohtsuki S, Terasaki T. A novel relationship between creatine transport at the blood-brain and blood-retinal barriers, creatine biosynthesis, and its use for brain and retinal energy homeostasis. Subcell Biochem 2007, 46:83-98. full_text, 18652073.
23. Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. J Pharmacol Exp Ther 1996, 277:1550-1559.
24. Kitazawa T, Hosoya K, Takahashi T, Sugiyama Y, Terasaki T. In-vivo and in-vitro evidence of a carrier-mediated efflux transport system for oestrone-3-sulphate across the blood-cerebrospinal fluid barrier. J Pharm Pharmacol 2000, 52:281-288. 10.1211/0022357001773968, 10757415.
25. Hosoya K, Tetsuka K, Nagase K, Tomi M, Saeki S, Ohtsuki S, Takanaga H, Yanai N, Obinata M, Kikuchi A, et al. Conditionally immortalized brain capillary endothelial cell lines established from a transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. AAPS PharmSci 2000, 2:E27. 10.1208/ps020328, 2761138, 11741243.
26. Hosoya K, Takashima T, Tetsuka K, Nagura T, Ohtsuki S, Takanaga H, Ueda M, Yanai N, Obinata M, Terasaki T. mRna expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J Drug Target 2000, 8:357-370. 10.3109/10611860008997912, 11328662.
27. Kitazawa T, Hosoya K, Watanabe M, Takashima T, Ohtsuki S, Takanaga H, Ueda M, Yanai N, Obinata M, Terasaki T. Characterization of the amino acid transport of new immortalized choroid plexus epithelial cell lines: a novel in vitro system for investigating transport functions at the blood-cerebrospinal fluid barrier. Pharm Res 2001, 18:16-22. 10.1023/A:1011014424212, 11336348.
28. Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, Hosoya K. New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov Today 2003, 8:944-954. 10.1016/S1359-6446(03)02858-7, 14554158.
29. O'Kane RL, Vina JR, Simpson I, Zaragoza R, Mokashi A, Hawkins RA. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. Am J Physiol Endocrinol Metab 2006, 291:E412-419.
30. Stoll J, Wadhwani KC, Smith QR. Identification of the cationic amino acid transporter (System y+) of the rat blood-brain barrier. J Neurochem 1993, 60:1956-1959. 10.1111/j.1471-4159.1993.tb13428.x, 8473910.
31. Aoyagi K. Inhibition of arginine synthesis by urea: a mechanism for arginine deficiency in renal failure which leads to increased hydroxyl radical generation. Mol Cell Biochem 2003, 244:11-15. 10.1023/A:1022479017087, 12701804.
32. Kamada Y, Nagaretani H, Tamura S, Ohama T, Maruyama T, Hiraoka H, Yamashita S, Yamada A, Kiso S, Inui Y, et al. Vascular endothelial dysfunction resulting from L-arginine deficiency in a patient with lysinuric protein intolerance. J Clin Invest 2001, 108:717-724. 209374, 11544277.
33. Zlokovic BV, Begley DJ, Chain DG. Blood-brain barrier permeability to dipeptides and their constituent amino acids. Brain Res 1983, 271:65-71. 10.1016/0006-8993(83)91365-3, 6883121.
34. Furuya S, Watanabe M. Novel neuroglial and glioglial relationships mediated by L-serine metabolism. Arch Histol Cytol 2003, 66:109-121. 10.1679/aohc.66.109, 12846552.
35. Yang JH, Wada A, Yoshida K, Miyoshi Y, Sayano T, Esaki K, Kinoshita MO, Tomonaga S, Azuma N, Watanabe M, et al. Brain-specific Phgdh Deletion Reveals a Pivotal Role for L-Serine Biosynthesis in Controlling the Level of D-Serine, an N-methyl-D-aspartate Receptor Co-agonist, in Adult Brain. J Biol Chem 2010, 285:41380-41390. 10.1074/jbc.M110.187443, 20966073.
36. Hosoya K, Sugawara M, Asaba H, Terasaki T. Blood-brain barrier produces significant efflux of L-aspartic acid but not D-aspartic acid: in vivo evidence using the brain efflux index method. J Neurochem 1999, 73:1206-1211. 10.1046/j.1471-4159.1999.0731206.x, 10461913.
37. Kakee A, Takanaga H, Terasaki T, Naito M, Tsuruo T, Sugiyama Y. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier. J Neurochem 2001, 79:110-118. 10.1046/j.1471-4159.2001.00540.x, 11595763.
38. Lee NY, Kang YS. The brain-to-blood efflux transport of taurine and changes in the blood-brain barrier transport system by tumor necrosis factor-alpha. Brain Res 2004, 1023:141-147. 10.1016/j.brainres.2004.07.033, 15364029.
39. Takanaga H, Tokuda N, Ohtsuki S, Hosoya K, Terasaki T. ATA2 is predominantly expressed as system A at the blood-brain barrier and acts as brain-to-blood efflux transport for L-proline. Mol Pharmacol 2002, 61:1289-1296. 10.1124/mol.61.6.1289, 12021389.
40. Kanai Y. Family of neutral and acidic amino acid transporters: molecular biology, physiology and medical implications. Curr Opin Cell Biol 1997, 9:565-572. 10.1016/S0955-0674(97)80035-X, 9261059.
41. O'Kane RL, Martinez-Lopez I, DeJoseph MR, Vina JR, Hawkins RA. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999, 274:31891-31895.
42. Benrabh H, Lefauconnier JM. Glutamate is transported across the rat blood-brain barrier by a sodium-independent system. Neurosci Lett 1996, 210:9-12. 10.1016/0304-3940(96)12635-5, 8762179.
43. Lee WJ, Hawkins RA, Vina JR, Peterson DR. Glutamine transport by the blood-brain barrier: a possible mechanism for nitrogen removal. Am J Physiol 1998, 274:C1101-1107.
44. Tetsuka K, Takanaga H, Ohtsuki S, Hosoya K, Terasaki T. The l-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. J Neurochem 2003, 87:891-901. 10.1046/j.1471-4159.2003.02063.x, 14622120.
45. Takanaga H, Ohtsuki S, Hosoya K, Terasaki T. GAT2/BGT-1 as a system responsible for the transport of gamma-aminobutyric acid at the mouse blood-brain barrier. J Cereb Blood Flow Metab 2001, 21:1232-1239. 10.1097/00004647-200110000-00012, 11598501.
46. Smith KE, Borden LA, Wang CH, Hartig PR, Branchek TA, Weinshank RL. Cloning and expression of a high affinity taurine transporter from rat brain. Mol Pharmacol 1992, 42:563-569.
47. Chen NH, Reith ME, Quick MW. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 2004, 447:519-531. 10.1007/s00424-003-1064-5, 12719981.
48. Saltarelli MD, Bauman AL, Moore KR, Bradley CC, Blakely RD. Expression of the rat brain creatine transporter in situ and in transfected HeLa cells. Dev Neurosci 1996, 18:524-534. 10.1159/000111450, 8940628.
49. Schloss P, Mayser W, Betz H. The putative rat choline transporter CHOT1 transports creatine and is highly expressed in neural and muscle-rich tissues. Biochem Biophys Res Commun 1994, 198:637-645. 10.1006/bbrc.1994.1093, 8297374.
50. Tachikawa M, Fujinawa J, Takahashi M, Kasai Y, Fukaya M, Sakai K, Yamazaki M, Tomi M, Watanabe M, Sakimura K, et al. Expression and possible role of creatine transporter in the brain and at the blood-cerebrospinal fluid barrier as a transporting protein of guanidinoacetate, an endogenous convulsant. J Neurochem 2008, 107:768-778. 10.1111/j.1471-4159.2008.05652.x, 18761709.
51. Tachikawa M, Kasai Y, Takahashi M, Fujinawa J, Kitaichi K, Terasaki T, Hosoya K. The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process. J Neurochem 2008, 107:432-442. 10.1111/j.1471-4159.2008.05641.x, 18752646.
52. Shojaiefard M, Christie DL, Lang F. Stimulation of the creatine transporter SLC6A8 by the protein kinases SGK1 and SGK3. Biochem Biophys Res Commun 2005, 334:742-746. 10.1016/j.bbrc.2005.06.164, 16036218.
53. Dodd JR, Christie DL. Selective amino acid substitutions convert the creatine transporter to a gamma-aminobutyric acid transporter. J Biol Chem 2007, 282:15528-15533. 10.1074/jbc.M611705200, 17400549.
54. Dominy J, Thinschmidt JS, Peris J, Dawson R, Papke RL. Taurine-induced long-lasting potentiation in the rat hippocampus shows a partial dissociation from total hippocampal taurine content and independence from activation of known taurine transporters. J Neurochem 2004, 89:1195-1205. 10.1111/j.1471-4159.2004.02410.x, 15147512.
55. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain [corrected]. J Biol Chem 1993, 268:2106-2112.
56. Tachikawa M, Kasai Y, Yokoyama R, Fujinawa J, Ganapathy V, Terasaki T, Hosoya K. The blood-brain barrier transport and cerebral distribution of guanidinoacetate in rats: involvement of creatine and taurine transporters. J Neurochem 2009, 111:499-509. 10.1111/j.1471-4159.2009.06332.x, 19682207.
57. Tomi M, Tajima A, Tachikawa M, Hosoya K. Function of taurine transporter (Slc6a6/TauT) as a GABA transporting protein and its relevance to GABA transport in rat retinal capillary endothelial cells. Biochim Biophys Acta 2008, 1778:2138-2142. 10.1016/j.bbamem.2008.04.012, 18501699.
58. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004, 21:976-981. 10.1023/B:PHAM.0000029286.45788.ad, 15212162.
59. Kimura N, Masuda S, Katsura T, Inui K. Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmacol 2009, 77:1429-1436. 10.1016/j.bcp.2009.01.010, 19426682.
60. Lightman SL, Palestine AG, Rapoport SI, Rechthand E. Quantitative assessment of the permeability of the rat blood-retinal barrier to small water-soluble non-electrolytes. J Physiol 1987, 389:483-490. 1192091, 3119820.
61. Sora I, Richman J, Santoro G, Wei H, Wang Y, Vanderah T, Horvath R, Nguyen M, Waite S, Roeske WR, et al. The cloning and expression of a human creatine transporter. Biochem Biophys Res Commun 1994, 204:419-427. 10.1006/bbrc.1994.2475, 7945388.
62. Guimbal C, Kilimann MW. A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J Biol Chem 1993, 268:8418-8421.
63. Belanger M, Asashima T, Ohtsuki S, Yamaguchi H, Ito S, Terasaki T. Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochem Int 2007, 50:95-101. 10.1016/j.neuint.2006.07.005, 16956696.
64. Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci 2004, 20:144-160. 10.1111/j.1460-9568.2004.03478.x, 15245487.
65. Braissant O, Henry H, Loup M, Eilers B, Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Brain Res Mol Brain Res 2001, 86:193-201. 10.1016/S0169-328X(00)00269-2, 11165387.
66. Balestrino M, Rebaudo R, Lunardi G. Exogenous creatine delays anoxic depolarization and protects from hypoxic damage: dose-effect relationship. Brain Res 1999, 816:124-130. 10.1016/S0006-8993(98)01131-7, 9878706.
67. Brewer GJ, Wallimann TW. Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons. J Neurochem 2000, 74:1968-1978. 10.1046/j.1471-4159.2000.0741968.x, 10800940.
68. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999, 5:347-350. 10.1038/6568, 10086395.
69. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 1999, 157:142-149. 10.1006/exnr.1999.7049, 10222117.
70. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci 1998, 18:156-163.
71. Schmidt A, Marescau B, Boehm EA, Renema WK, Peco R, Das A, Steinfeld R, Chan S, Wallis J, Davidoff M, et al. Severely altered guanidino compound levels, disturbed body weight homeostasis and impaired fertility in a mouse model of guanidinoacetate N-methyltransferase (GAMT) deficiency. Hum Mol Genet 2004, 13:905-921. 10.1093/hmg/ddh112, 15028668.
72. Torremans A, Marescau B, Possemiers I, Van Dam D, D'Hooge R, Isbrandt D, De Deyn PP. Biochemical and behavioural phenotyping of a mouse model for GAMT deficiency. J Neurol Sci 2005, 231:49-55. 10.1016/j.jns.2004.12.014, 15792821.
73. Neu A, Neuhoff H, Trube G, Fehr S, Ullrich K, Roeper J, Isbrandt D. Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. Neurobiol Dis 2002, 11:298-307. 10.1006/nbdi.2002.0547, 12505422.
74. Keep RF, Xiang J. Choroid plexus taurine transport. Brain Res 1996, 715:17-24. 10.1016/0006-8993(95)01294-X, 8739618.
75. Sijens PE, Verbruggen KT, Oudkerk M, van Spronsen FJ, Soorani-Lunsing RJ. 1H MR spectroscopy of the brain in Cr transporter defect. Mol Genet Metab 2005, 86:421-422. 10.1016/j.ymgme.2005.08.004, 16169765.
76. Braissant O, Henry H. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: A review. J Inherit Metab Dis 2008, 31:230-239.
77. Verbruggen KT, Sijens PE, Schulze A, Lunsing RJ, Jakobs C, Salomons GS, van Spronsen FJ. Successful treatment of a guanidinoacetate methyltransferase deficient patient: findings with relevance to treatment strategy and pathophysiology. Mol Genet Metab 2007, 91:294-296. 10.1016/j.ymgme.2007.03.006, 17466557.
78. Mancardi MM, Caruso U, Schiaffino MC, Baglietto MG, Rossi A, Battaglia FM, Salomons GS, Jakobs C, Zara F, Veneselli E, Gaggero R. Severe epilepsy in X-linked creatine transporter defect (CRTR-D). Epilepsia 2007, 48:1211-1213. 10.1111/j.1528-1167.2007.01148.x, 17553121.
79. Rosenberg EH, Almeida LS, Kleefstra T, deGrauw RS, Yntema HG, Bahi N, Moraine C, Ropers HH, Fryns JP, deGrauw TJ, et al. High prevalence of SLC6A8 deficiency in X-linked mental retardation. Am J Hum Genet 2004, 75:97-105. 10.1086/422102, 1182013, 15154114.
80. Rosenberg EH, Martinez Munoz C, Betsalel OT, van Dooren SJ, Fernandez M, Jakobs C, deGrauw TJ, Kleefstra T, Schwartz CE, Salomons GS. Functional characterization of missense variants in the creatine transporter gene (SLC6A8): improved diagnostic application. Hum Mutat 2007, 28:890-896. 10.1002/humu.20532, 17465020.
81. Almeida LS, Salomons GS, Hogenboom F, Jakobs C, Schoffelmeer AN. Exocytotic release of creatine in rat brain. Synapse 2006, 60:118-123. 10.1002/syn.20280, 16715490.
82. De Deyn PP, Vanholder R, Eloot S, Glorieux G. Guanidino compounds as uremic (neuro)toxins. Semin Dial 2009, 22:340-345. 10.1111/j.1525-139X.2009.00577.x, 19708978.
83. De Deyn PP, Marescau B, Cuykens JJ, Van Gorp L, Lowenthal A, De Potter WP. Guanidino compounds in serum and cerebrospinal fluid of non-dialyzed patients with renal insufficiency. Clin Chim Acta 1987, 167:81-88. 10.1016/0009-8981(87)90088-X, 3665089.
84. De Deyn PP, Marescau B, D'Hooge R, Possemiers I, Nagler J, Mahler C. Guanidino compound levels in brain regions of non-dialyzed uremic patients. Neurochem Int 1995, 27:227-237. 10.1016/0197-0186(95)00041-6, 8520461.
85. De Deyn PP, D'Hooge R, Van Bogaert PP, Marescau B. Endogenous guanidino compounds as uremic neurotoxins. Kidney Int Suppl 2001, 78:S77-83.
86. Ku CP, Passow H. Creatine and creatinine transport in old and young human red blood cells. Biochim Biophys Acta 1980, 600:212-227. 10.1016/0005-2736(80)90426-5, 7397170.
87. Nakayama H, Kitaichi K, Ito Y, Hashimoto K, Takagi K, Yokoi T, Ozaki N, Yamamoto T, Hasegawa T. The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats. Brain Res 2007, 1184:260-269. 10.1016/j.brainres.2007.09.072, 17988657.